
Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase 1/2 multicenter trial (NCT01631552) in patients with advanced epithelial cancers. This report summarizes the safety data from the overall safety population (OSP) and efficacy data, including additional disease cohorts not published previously...
Like
Save
Share